Cardiol says $31 million of gross proceeds from an October 2025 private placement and a January 2026 bought deal funds it through its Phase III pericarditis trial. The release names no underwriter or placement agent.
Latest Cardiol Therapeutics news
We have not published a story on Cardiol Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Dec 31, 2025 (40-F): cash and equivalents C$21.4 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Cardiol Therapeutics
Has Cardiol Therapeutics raised money recently?
Our latest story on this, dated Apr 1, 2026: "Cardiol Therapeutics reports $31 million raised and cash runway into Q4 2027". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Cardiol Therapeutics?
Cardiol Therapeutics Inc. trades under the ticker CRDL on TSX.
Where is Cardiol Therapeutics listed?
Cardiol Therapeutics Inc. is listed on TSX. Our directory also records these other listings: GETTEX:CT9; LS:A2PA9E; LSX:A2PA9E; NASDAQ:CRDL; NEO:CRDL.
What is the SEC CIK of Cardiol Therapeutics?
The SEC Central Index Key (CIK) for Cardiol Therapeutics Inc. is 1702123. Its filings are on SEC EDGAR.
How many shares does Cardiol Therapeutics have outstanding?
65,352,279 shares as of 2023-12-31, per the cover page of its 20-F filed 2024-04-01.
Which country or territory is Cardiol Therapeutics listed under?
Our directory records Cardiol Therapeutics Inc. under Canada.
What does Cardiol Therapeutics do?
Our directory classifies Cardiol Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Cardiol Therapeutics?
The ISIN recorded for Cardiol Therapeutics Inc. is CA14161Y2006.
Does aibio.space cover Cardiol Therapeutics?
aibio.space lists Cardiol Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Cardiol Therapeutics incorporated?
SEC records list its state or country of incorporation as A6.
What is the latest Cardiol Therapeutics (CRDL) stock news?
Our latest story on Cardiol Therapeutics, dated Apr 1, 2026: "Cardiol Therapeutics reports $31 million raised and cash runway into Q4 2027". Cardiol says $31 million of gross proceeds from an October 2025 private placement and a January 2026 bought deal funds it through its Phase III pericarditis trial. The release names no underwriter or placement agent. Source.
How long will Cardiol Therapeutics's cash last?
From our story of Apr 1, 2026: The update says the company raised aggregate gross proceeds of $31 million, which it says provides a cash runway into the fourth quarter of 2027. Source.
Is Cardiol Therapeutics a smaller reporting company?
SEC records list Cardiol Therapeutics Inc.'s filer category as: <br>Emerging growth company.
Where is Cardiol Therapeutics headquartered?
SEC records list its business address as 602-2265 UPPER MIDDLE ROAD EAST, OAKVILLE, Ontario, Canada, L6H 0G5.
When does Cardiol Therapeutics's fiscal year end?
Cardiol Therapeutics Inc.'s fiscal year ends on December 31, per SEC records.
Investor discussion: Cardiol Therapeutics
Members talk about Cardiol Therapeutics (CRDL). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Cardiol Therapeutics, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TSX:CRDL on TradingView.
SEC filings and registration
SEC name
Cardiol Therapeutics Inc.
CIK
1702123
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Cardiol Therapeutics Inc. is a public biotech or pharmaceutical company listed on TSX under the ticker CRDL, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio